CERES F&D

CERES F&D, established in 2018, positions itself as a pivotal player in the biopharmaceutical space, emphasizing high-quality and effective medicines. The company's dedication to maintaining superior standards, along with innovations in technology and a strategic focus on new product development, underlines its potential for industry disruption.

Specializing in the manufacture of Antibiotics and Immunosuppressant APIs, the company also boasts global rights for Alteogen's commercialized product, Tergase®, a human hyaluronidase. As a subsidiary of the leading Korean bioscience company, Alteogen, CERES F&D benefits from an established reputation and substantial industry expertise. Headquartered in South Korea, their strategic location supports their global outreach ambitions.

In terms of financial growth, the firm secured a KRW8.00 billion Series B investment on February 17, 2020, with participation from notable investors such as SJ Investment Partners, Magna Investment, Seoul Investment Partners, and K-Run Ventures. This substantial backing underscores investor confidence in the company’s potential and its strategic trajectory in the biotechnology and pharmaceuticals sector.